 Connection
Thomas Anchordoquy to Antineoplastic Agents
This is a "connection" page, showing publications Thomas Anchordoquy has written about Antineoplastic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.496 |
|
|
|
-
Smyth T, Kullberg M, Malik N, Smith-Jones P, Graner MW, Anchordoquy TJ. Biodistribution and delivery efficiency of unmodified tumor-derived exosomes. J Control Release. 2015 Feb 10; 199:145-55.
Score: 0.213
-
Tilden SG, Ricco MH, Hemann EA, Anchordoquy TJ. Exploiting a type III interferon response to improve chemotherapeutic safety and efficacy. Eur J Pharm Sci. 2025 Jan 01; 204:106974.
Score: 0.106
-
Betker JL, Angle BM, Graner MW, Anchordoquy TJ. The Potential of Exosomes From Cow Milk for Oral Delivery. J Pharm Sci. 2019 04; 108(4):1496-1505.
Score: 0.070
-
Anchordoquy TJ, Barenholz Y, Boraschi D, Chorny M, Decuzzi P, Dobrovolskaia MA, Farhangrazi ZS, Farrell D, Gabizon A, Ghandehari H, Godin B, La-Beck NM, Ljubimova J, Moghimi SM, Pagliaro L, Park JH, Peer D, Ruoslahti E, Serkova NJ, Simberg D. Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions. ACS Nano. 2017 01 24; 11(1):12-18.
Score: 0.062
-
Kullberg M, Mann K, Anchordoquy TJ. Targeting Her-2+ breast cancer cells with bleomycin immunoliposomes linked to LLO. Mol Pharm. 2012 Jul 02; 9(7):2000-8.
Score: 0.045
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|